News
New Alternative in the Treatment of Diffuse Large B-cell Lymphoma
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation, a wide range of treatment regimens is available. Recently, the addition of polatuzumab vedotin to rituximab and bendamustine therapy has shown promising efficacy in both registration studies and real-world clinical practice.
ASH 2020: Efficacy and Safety of Emicizumab in Long-term Follow-up
At the virtual meeting of the American Society of Hematology (ASH) in December 2020, the latest…
ASH 2020: Two Real-World Perspectives on Experiences with Emicizumab Prophylaxis
Data presented at the ASH 2020 congress bring interesting insights regarding the administration of…
Frequency of Mutations in Genes Predisposing to Ovarian Cancer in the Czech Population
The authors of a Czech study evaluating the occurrence of mutations in tumor-predisposing genes for…
Factors Influencing the Occurrence of Prosthetic Stomatitis in Patients with Complete Denture
Dental dentures are removable replacements made for partial or complete loss of teeth. Quality…
Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU
In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil…
Long-term results of alpha-1-antitrypsin deficiency treatment – RAPID program
RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of…
How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated…
Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal…
Perioperative Management of Bleeding in Patients with von Willebrand Disease Using Coagulation Factors
Von Willebrand disease is one of the most common congenital bleeding disorders. It is a…